Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating)’s share price fell 5% during mid-day trading on Friday . The stock traded as low as $55.17 and last traded at $55.36. 21,754 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,527,777 shares. The stock had previously closed at $58.29.
Analyst Ratings Changes
Several research firms have recently issued reports on AXSM. Morgan Stanley lowered their price objective on Axsome Therapeutics from $74.00 to $73.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 8th. Guggenheim increased their target price on shares of Axsome Therapeutics from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $210.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, October 4th. Jefferies Financial Group decreased their target price on shares of Axsome Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, September 30th. Finally, Mizuho increased their target price on shares of Axsome Therapeutics from $76.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $109.45.
Axsome Therapeutics Price Performance
The stock has a market capitalization of $2.56 billion, a P/E ratio of -14.53 and a beta of 1.75. The business has a fifty day simple moving average of $51.22 and a 200-day simple moving average of $42.51. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.20 and a current ratio of 4.19.
Hedge Funds Weigh In On Axsome Therapeutics
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.